Alnylam reports positive results for RNAi therapy

John Carroll

Cambridge, MA-based Pharmaceuticals says it garnered interim data from a Phase I study of ALN-TTRsc, an targeting the transthyretin gene for the treatment of TTR-mediated amyloidosis.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS